José María Viéitez

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

Jaafar Bennouna, Javier Sastre, Dirk Arnold et al. · The Lancet Oncology · 2012 · 1.2K citations · Full text

Gastrointestinal Oncology, Medicine, Randomised Phase 3 +7

Oral Capecitabine Compared With Intravenous Fluorouracil Plus Leucovorin in Patients With Metastatic Colorectal Cancer: Results of a Large Phase III Study

Eric Van Cutsem, Chris Twelves, Jim Cassidy et al. · Journal of Clinical Oncology · 2001 · 1K citations

Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients

H. Cortés-Funes, Carlos Gegúndez Gómez, Rafael Rosell et al. · Annals of Oncology · 2005 · 231 citations

Medicine, Pathology, Bronchial Neoplasm +7

Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer

Julieta Grasselli, Élena Elez, Ginevra Caratù et al. · Annals of Oncology · 2017 · 189 citations · Full text

Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings

Stefan Kubicka, Richard Greil, Thierry André et al. · Annals of Oncology · 2013 · 101 citations · Full text

Gastrointestinal Oncology, Medicine, Pathology +8